California V1 CBD Flower
California V1 CBD Flower x3
Mind CBD Sachets
Analysis Flower CBD California V1

California Dream (Indoor) - CBD 16.9%

Swiss California Dream grown indoors and hand-harvested, with 16.9% CBD. A 100% natural flower in a lovely light green, with tangy, sweet citrus flavours: a highly aromatic sativa-dominant hybrid for fans of sunny notes.
Regular price 15,80 € Sale price instead of 24,00 €

Availability: In stock – Ships within 24h

7,90 €/g
Tax included. Shipping calculated at checkout.
En Stock !
Livré en France sous 2 à 3 jours
Vous n'êtes pas en France ?

Summary

California Dream CBD Flower Grown indoors in Switzerland (Indoor)

  • Flavours: Citrus, Tangy, Sweet
  • CBD 16.9%
  • Sativa-dominant hybrid
  • Hand-harvested

See all products:

Details

California Dream Indoor CBD Flower

Here is a 100% natural flower of Swiss origin with a magnificent light green colour.

This flower has scents of tropical fruits such as mango and pineapple. It is also well endowed with CBD, at a level of 16.9%.

Superb aroma, very firm and compact buds, particularly careful trimming.

Cultivation method
Organic cultivation indoors in Switzerland (Indoor).

Species
Sativa-dominant hybrid.

Concentration

  • CBD: 16.94%
  • THC: 0.27%

Certification
California Dream CBD flowers grown in Switzerland, then certified by an independent, GMP-approved European laboratory.

Legislation
100% legal product in the European Union. This variety is a hybrid derived from varieties authorised in the European catalogue.

*Non-contractual photos, taken by us from the batch currently on sale*

Flavours

California Dream Indoor CBD Flower 16.9%

  • Fruity
  • Pine
  • Sweet

Similar products

Discover other Indoor CBD flowers:

Sources and references (4)

Official and scientific sources on the regulation, safety, composition and quality of this type of product. They are provided for information and are not health claims.

  1. MILDECA (2021). L'indispensable sur... le cannabidiol (CBD). MILDECA — drogues.gouv.fr. View the source
  2. MILDECA (2023). Le CBD. drogues.gouv.fr (Mission interministérielle de lutte contre les drogues et les conduites addictives). View the source
  3. Chevallier C, Charuel L, Richeval C, Chaouachi L, Del Valle L, Eiden C, Gaulier JM, Batisse A (CEIP-A Paris, Lyon, Montpellier ; CHU Lille) (2023). Cannabidiol : analyse de produits « CBD non pharmaceutiques » disponibles sur le marché en France. MILDECA — drogues.gouv.fr (rapport CEIP-A financé par la MILDECA). View the source
  4. Dryburgh LM, Bolan NS, Grof CPL, et al. (2018). Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects. British Journal of Clinical Pharmacology. View the source

Recently viewed